Cryo Cell International Inc: Form 10-K for the period ended Nov 30, 2019
Filed with the SEC on Feb 28, 2020 and accepted by EDGAR at Feb 28, 2020, 21:50 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2018-12-01 to 2019-11-30 | $31.8m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 12 months2018-12-01 to 2019-11-30 | $10.0m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2018-12-01 to 2019-11-30 | $30.1k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2018-12-01 to 2019-11-30 | $14.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2018-12-01 to 2019-11-30 | $5.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2018-12-01 to 2019-11-30 | $1.7m | us-gaap:InterestExpense |
| Income tax | 12 months2018-12-01 to 2019-11-30 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2018-12-01 to 2019-11-30 | $2.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2018-12-01 to 2019-11-30 | $0.27 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2018-12-01 to 2019-11-30 | $0.29 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2018-12-01 to 2019-11-30 | 8,412,414 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2018-12-01 to 2019-11-30 | $6.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-12-01 to 2019-11-30 | $662.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2018-12-01 to 2019-11-30 | $992.2k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-11-30 | $6.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-11-30 | $15.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-11-30 | $42.9m | us-gaap:Assets |
| Current liabilities | At period end2019-11-30 | $15.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-11-30 | $49.8m | us-gaap:Liabilities |
| Long-term debt | At period end2019-11-30 | $9.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2019-11-30 | −$7.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-20-056695. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.